GRTS - Why Is Vaccine Focused Gritstone bio Stock Trading Higher Today? | Benzinga
Gritstone Bio Inc (NASDAQ: GRTS) received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study evaluating its self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets to protect against COVID-19.
The agreement, which is valued at up to $433 million, was awarded as part ...